Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 2, 2011, Pages 111-117

  Esteghamati, Alireza ^a   Noshad, Sina ^a   Khalilzadeh, Omid ^a,b   Khalili, Mohammad ^a   Zandieh, Ali ^a   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ALANINE TRANSAMINASE; ANTHROPOMETRY; ASPARTATE AMINOTRANSFERASES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 79953068941     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2010.0066     Document Type: Article

References (46)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355. (Pubitemid 20360647)
3. Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000;355:591-592. (Pubitemid 30099460)
4. Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum en-zyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978;70:248-258. (Pubitemid 9005446)
5. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci 1988;33:1601-1614. (Pubitemid 19095465)
6. Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, Fredriksson J, Yki-Jarvinen H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004;47:1360-1369. (Pubitemid 39232420)
7. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005;28:2913-2918. (Pubitemid 43942924)
8. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51:1889-1895. (Pubitemid 34564303)
9. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988;31:798-805. (Pubitemid 19004929)
10. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Jr., Kempf J, Zinman B, Haffner SM. Eleva-tions in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004;53: 2623-2632. (Pubitemid 39299271)
11. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004;53:2855-2860. (Pubitemid 39425910)
12. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-1719.
13. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289:3000-3004. (Pubitemid 37430103)
14. Clark JM, Brancati FL, Diehl AM. The prevalence and eti-ology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967. (Pubitemid 36733754)
15. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M. Should nonalcoholic fatty liver disease be in-cluded in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008;31:562-568.
16. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Naka-jima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the met-abolic syndrome and visceral fat accumulation. Am J Gas-troenterol 2007;102:2708-2715. (Pubitemid 350179336)
17. Torres DM, Harrison SA. Diagnosis and therapy of nonal-coholic steatohepatitis. Gastroenterology 2008;134:1682-1698.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trea-cher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
19. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sen-sitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410. (Pubitemid 32269192)
20. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24:460-464. (Pubitemid 32198413)
21. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, Hori Y, Yano Y, Adachi Y. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001;24:362-365. (Pubitemid 32119139)
22. Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495. (Pubitemid 38680001)
23. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-S69.
24. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38(Suppl 2):S44-S48. (Pubitemid 38328164)
25. Lentjes EG, Harff GA, Backer ET. Evaluation of the Hitachi 704 automatic analyzer. Clin Chem 1987;33:2089-2092.
26. Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernandez-Real JM. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004;60:256-263. (Pubitemid 38200909)
27. Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology 2007;46:158-165. (Pubitemid 47171932)
28. Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T, Kostense PJ, Heine RJ. Liver alanine aminotransferase, insulin resistance and endothelial dys-function in normotriglyceridaemic subjects with type 2 dia-betes mellitus. Eur J Clin Invest 2005;35:369-374. (Pubitemid 40826835)
29. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Association of serum gamma-glutamyltransferase and alanine amino-transferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 2009;25: 64-69.
30. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292. (Pubitemid 36667307)
31. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63. (Pubitemid 30022895)
32. Schwartz B, Jacobs DR, Jr., Moran A, Steinberger J, Hong CP, Sinaiko AR. Measurement of insulin sensitivity in children comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care 2008;31:783-788.
33. Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G Comparative evaluation of simple indices of insulin resistance. Metabolism 2004;53:1522-1526. (Pubitemid 39556363)
34. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Sta-filas PC, Kanaki A, Kazakos K, Yovos J, Bakris GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens 2007;21:709-716. (Pubitemid 47335301)
35. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-1346.
36. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009;87:679-695.
37. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:545-563.
38. Tilg H The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010;28:179-185.
39. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Min-grone G Insulin clearance in obesity. J Am Coll Nutr 2003; 22:487-493.
40. Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: Clinical features and independent risk factors in diabetic fatty liver patients. He-patobiliary Pancreat Dis Int 2005;4:389-392.
41. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-1466. (Pubitemid 28264666)
42. Stein LL, Dong MH, Loomba R Insulin sensitizers in non-alcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907.
43. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-265. (Pubitemid 38293314)
44. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
45. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. (Pubitemid 32591518)
46. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445.